{
  "eval_id": "S21",
  "eval_file": "evals/single/S21.json",
  "timestamp": "2025-09-18T16:40:23.817055Z",
  "model": "gpt-4.1",
  "temperature": 0.6,
  "rep_input": "Clinically, what are the on-label points I should know about Trodelvy in HR+/HER2- after prior CDK4/6?",
  "model_output": "Trodelvy is indicated for adults with HR-positive, HER2-negative advanced breast cancer after endocrine therapy and at least two prior systemic therapies, including a CDK4/6 inhibitor where available. Efficacy and safety are based on the TROPiCS-02 study population. Please send the SmPC or EMA summary by email if you want to highlight specific data."
}